DNAJC7 Antibody #80718
- WB
Supporting Data
| REACTIVITY | H M R |
| SENSITIVITY | Endogenous |
| MW (kDa) | 62 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
DNAJC7 Antibody recognizes endogenous levels of total DNAJC7 protein.
Species Reactivity:
Human, Mouse, Rat
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly487 of human DNAJC7 protein. Antibodies are purified by protein A and peptide affinity chromatography.
Background
DnaJ homolog subfamily C member 7 (DNAJC7) is part of a family of DNAJ proteins that act as molecular chaperones to regulate protein maintenance and quality control via its regulation of HSP70 chaperones (1). DNAJ proteins contain a J-domain, an approximately 70 amino acid region containing 4 alpha helices. The J-domain is critical for stimulation of ATP hydrolysis of HSP70 (2). There are some 50 DNAJ family members that are grouped into 1 of 3 classes based on domain structures. DNAJC7 is a Class III DNAJ protein (3). The human gene that encodes the protein, DNAJC7, is genetically linked to amyotrophic lateral sclerosis (ALS), a late-onset neurodegenerative disease characterized by degeneration of motor neurons (4,5). As quality control proteins, DNAJ dysfunction may result in aberrant folding of newly synthesized polypeptides or altered clearance of degraded proteins, contributing to disease pathology.
- Kakkar, V. et al. (2012) Curr Top Med Chem 12, 2479-90.
- Tsai, J. and Douglas, M.G. (1996) J Biol Chem 271, 9347-54.
- Zarouchlioti, C. et al. (2018) Philos Trans R Soc Lond B Biol Sci 373, 20160534. doi: 10.1098/rstb.2016.0534.
- Farhan, S.M.K. et al. (2019) Nat Neurosci 22, 1966-1974.
- Jih, K.Y. et al. (2020) Neurol Genet 6, e503.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.